What’s new

• Board approved 7 million warrants to promoter entity Essix Biosciences at ₹196 each, raising up to ₹137.2 cr.
• Warrants convertible into equity within 18 months, leading to ~7% dilution.
• Shareholder approval sought at EGM on August 5.

Why it matters

For a company with trailing PAT down 93%, the promoter is putting in 7% of market cap in fresh equity. That's a strong confidence signal, though the eventual conversion will dilute existing holders.

What we’re watching

• Shareholder approval at the August 5 EGM.
• Conversion timeline and stock price relative to ₹196.
• Use of proceeds — likely for debt reduction or growth capex.

The full read

Promoter group Essix Biosciences is putting ₹137.2 crore into Ind-Swift Laboratories. That's 7% of the company's ₹1,747 crore market cap. A material bet. The board approved 7 million warrants at ₹196 apiece, convertible within 18 months. The timing stands out because trailing PAT sank 93% over the past year, yet the March quarter posted a ₹15 crore profit — a stark contrast that makes the promoter's commitment all the more telling. The promoter's willingness to inject fresh capital signals conviction. It also adds a 7% dilution to the equity base if all warrants convert. Shareholder approval is needed at an August 5 EGM. Hardly a cheap signal. If the stock stays above ₹196, the promoter's stake grows; if not, the warrants lapse. Either way, the move provides a capital cushion and reduces financial uncertainty.

Primary source: BSE · NSE

What’s new

• Board to meet July 10 to consider raising funds via equity or convertible securities.
• Options include preferential issue, rights issue, or QIP.
• Previous preferential issue warrants lapsed; non-promoter HCP sold 7.5% stake in April.

Why it matters

The company is again seeking capital after a failed earlier issue and a large non-promoter exit. Without disclosed quantum, the meeting signals imminent dilution, which could pressure the stock. Low debt gives Ind-Swift some room to negotiate terms, but the key will be pricing and promoter participation.

What we’re watching

• Size and pricing of the proposed issue.
• Whether promoters participate after the previous warrant lapse.
• Any further stake sales by HCP Investments.

The full read

Ind-Swift Laboratories will ask its board on July 10 to approve a fund raise, yet it has not said how much or at what price. The options on the table: a preferential issue, a rights issue, or a QIP. The meeting arrives months after a previous preferential issue saw its warrants lapse, and after HCP Investments, a non-promoter, sold 7.5% of the company in April. The trading window is already shut for quarterly results and will stay shut until 48 hours after the board decision.

The company's market cap stands at ₹1,747 cr, but its profits have crashed 93.2% in the trailing period. The low debt (0.03 D/E) gives it some negotiating flexibility, but the board has to decide whether to price the issue attractively enough to get it done: the last one wasn't. This is a company that needs money and has to convince investors it can use it.

Primary source: BSE · NSE